《复牌表现》依利安达(01151.HK)获建滔集团溢价逾七成提私有化 股价飙61.5%
依利安达(01151.HK)获主要股之一建滔集团(00148.HK)提出自愿有条件现金要约价每股18.07元(较停牌前溢价逾七成)私有化,刺激前者股价今早复牌曾飙升至19.6元,创2012年8月以来新高,现造17.12元,急涨61.5%,一向稀疏成交仅增至9.6万股,涉额164万元。相反,建滔反覆续跌0.9%报17.68元。
建滔集团与依利安达联合公布,建滔计划以每股18.07元(较停牌前溢价70.47%元)私有化依利安达,涉及总代价8.91亿元。建滔声明认为,依利安达股份的交易价及成交量均不理想,令股东难以在场内进行大型出售,促使建滔集团增加其於依利安达股权,以便与公司产生更好协同效应。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.